amylyx pharmaceutical corp logo

Amylyx Pharmaceutical Corp.

Amylyx is an IND-enabling stage pharmaceutical company dedicated to providing innovative, disease-modifying solutions to neurodegenerative diseases.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://amylyx.com
Founded2013
Disease Focus
Development StageClinical
STOCK CODENon Listed
Address
210 Broadway #201, Cambridge, MA 02139
Massachusetts
United States
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

Oct 2017, The Alzheimers Association and Alzheimers Drug Discovery Foundation fund Amylyx Pharmaceuticals $1.85 million grant to support a phase 2 clinical trial of AMX0035.

Aug 2016, Amylyx completed a $5 million Series A financing led by Morningside Venture, ALS Investment Fund and former Genzyme CEO Henri Termeer as well as new and previous private investors.

In Jul 2016, Amylyx recieved $2.96 Mn grant from the ALS Association and ALS Finding a Cure, to fund Ph II trial for AMX0035. Earlier in 2015, company raised $1.3 Mn and $600,000 from the ALS Finding a Cure Foundation and the Cure Alzheimers Fund.